Bedaquiline: a new weapon against MDR and XDR-TB
نویسندگان
چکیده
منابع مشابه
Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use.
1 Blasi F, Dara M, van der Werf MJ, et al. Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. Eur Respir J 2013; 41: 491–494. 2 Blasi F, Barnes PJ, Gaga M, et al. Future directions for the ERS: Presidential plans. Eur Respir J 2013; 42: 875–880. 3 World Health Organization. Global Tuberculosis Report 2012. Geneva, WHO Press, 2012. Available from: www. who.int/tb/publicati...
متن کاملMDR-TB and XDR-TB: drug resistance and treatment outcomes.
The subject is quite topical, as TB programmes and clinicians are searching for solutions to treat MDR/XDR-TB most effectively. Recently published studies and a systematic review have shown that XDR-TB is associated with higher probability of failure and death, and lower probability of treatment success than MDR-TB [2–7]. The XDR-TB-defining drugs have been studied to evaluate their role in det...
متن کاملMDR / XDR - TB : where do we stand ?
Tuberculosis (TB) is one of the leading causes of death due to an infectious disease, second only to HIV/AIDS worldwide. It is estimated that approximately one third of the world’s population is infected with Mycobacterium tuberculosis, and 10% of infected individuals will develop active TB at some point in their lives. MDR-TB or multidrugresistant tuberculosis is a specific form of drug resist...
متن کاملA mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
tuberculosis prevention, care and control after 2015. Geneva, WHO, 2014. 13 World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision. Geneva, WHO, 2013. 14 Van Deun A, Maug AK, Bola V, et al. Rifampicin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51: 2633–2640. 15 Salje H, Andrews JR, Deo S, et al. The impo...
متن کاملDeclaration on palliative care and MDR/XDR-TB.
THE WORLD Health Organization (WHO) estimated a prevalence of 650 000 cases of multidrug-r esistant tuberculosis (MDR-TB) in 2010. Although efforts to improve cure rates in drug-resistant TB are vital, the global average reported cure rate was 53%. 1 Meanwhile, at least 150 000 deaths occur annually due to MDR-TB. 2 Efforts to provide palliative and end-of-life care to those suffering from this...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Basic & Clinical Pharmacology
سال: 2013
ISSN: 2319-2003
DOI: 10.5455/2319-2003.ijbcp20130301